Author name: Leonardo Arias

A Maine district court temporarily enjoined the pilot, which was set to take effect on Jan. 1, from kicking in. Still, the controversial payment experiment isn’t dead in the water, as the Trump administration quickly appealed the ruling.

The extension, released shortly before the flexibilities were set to expire at the end of 2025, gives regulators more time to finish permanent policies, the agencies said.

Executives at companies innovating a range of new robotic surgery platforms shared their progress and challenges in MedTech Dive’s series of profiles.

Stanley Bergman has worked at Henry Schein for 45 years, more than 35 of which he spent as CEO, and was due to retire at the end of 2025.

The expanded tax credits are officially dead after lawmakers failed to secure an extension before the end-of-year deadline. There’s still a chance, though a small one, that they could come back in 2026.

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with their new obesity pills this year.

After getting the crucial first-mover advantage with an FDA approval for a weight loss pill, Novo looks to win the market before rival Lilly can arrive with its own oral option for obesity.

The Illinois-based pharma has committed more than $1 billion in milestones to secure rights to ZG006 and join a who’s who of drugmakers targeting the DLL3 protein.

J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action could improve on existing therapies.

Según las Naciones Unidas, aproximadamente una de cada once personas en todo el mundo pasó hambre en 2023, y más de tres mil millones no pudieron costearse una alimentación saludable. Por lo tanto, se deben desarrollar métodos de producción de alimentos m&aa …